European Innovation Council

Funded by the European Union

HORIZON-EIC-2021-PATHFINDEROPEN-01

EIC Pathfinder Open 2021

VerSiLiB

Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

Start date: 01/04/2022, Duration 48 months

Deliverable D7.1
Public Website and Logo

Due date: 31/05/2022

Submission date: 25/05/2022

Responsible work package leader: Sanna Aikio, VTT, WP7

Responsible task leader: Sanna Aikio, VTT

Version: V1.0

Dissemination level: Public

This project has received funding from the European Union's European Innovation Council (EIC) under Horizon Europe program. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.

Authors

Sanna Aikio, VTT
Sanna Uusitalo, VTT

Revision log

Version	Date [DD/MM/YYYY]	Change
V0.1	20/05/2022	1st draft
V1.0	23/05/2022	Final version

Keywords

Project logo, Project public website

Executive summary

This deliverable report discusses the project logo and the public website. The logo, shown in the upper right-hand corner of this page, was designed. It provides a visual identity to the project and summarises the project idea in which both DNA and protein analytes are simultaneously analysed from a drop of blood. Project website in the address https://versilib.eu/ (Figure 1) was developed and published April 18, 2022. The aim of the website is to serve various stakeholder groups from general public to professionals. The first version of the website provides information on the received funding, project vision and aims, partners, events in which project is disseminated and contact information. More content, such as results and publications, will be added later.



Figure 1 'Home' sub-page of the project website.

Contents

1. Introduction 5
2. Project logo 5
3. Public website 5
3.1. ‘Home’ sub-page 5
3.2. ‘Project’ sub-page 6
3.3. ‘Partners’ sub-page 8
3.4. ‘Events’ sub-page 10
3.5. ‘Contacts’ sub-page 10
4. Accessibility and Visitor Analytics 11
5. Conclusions 11
6. Progress compared to the Description of Action 11

1. Introduction

Deliverable D7.1 'Public Website and Logo' is related to the project dissemination and communication activities in the tasks T7.1 'Coordination' and T7.5 'Dissemination and Communication strategy'. The objective was to

- Launch a public website that enables project communication and dissemination to various stakeholder groups including the general public.
- Design a project logo acting as a visual identifier in the communication, dissemination, and reporting activities.

The website content will be updated and developed based on the project's dissemination and communication strategy.

2. Project logo

The project logo, shown in Figure 2, was selected in the project kick-off meeting in April. Logo contains the project acronym as a text element and a graphical element summarising the project idea in which both nucleic acid and protein biomarkers are analysed simultaneously from a single drop of blood. To facilitate the use in various kinds of dissemination materials, two versions of the logo were designed: the primary dark blue version and an alternative white version to be used on dark backgrounds. The logo is used in the project website (see Figure 3) and project presentation and reporting templates. It will be widely used in all project communications.

Figure 2 Project logo. Left: Primary logo version. Right: Alternative logo that can be used on dark backgrounds.

3. Public website

Project website in the address https://versilib.eu/ was published May 18, 2022. The website consists of the following sub-pages 'Home', 'Project', 'Partners', 'Events', and 'Contact' that are discussed in detail below. The header in each sub-page contains the project logo. The footer contains the EIC logo, the EU emblem with the funding statement and the text

> 'Funded by the European Union's European Innovation Council under grant agreement No 101046217. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.'

3.1. 'Home' sub-page

The 'Home' sub-page (Figure 3) briefly summarizes the project aim and long-term vision going beyond the project. It also contains the basic funding information including the grant agreement number, duration, amount of the granted EU funding, funding program, and information of the granting authority. The image communicates that the project is related to the medical field and blood testing, and it is easily understandable by all audiences including the general public.



Figure 3 'Home' sub-page

3.2. 'Project' sub-page

The 'Project' sub-page (Figure 4) contains more detailed information of the project vision, core technical idea and aim. It can be accessed through the navigation link in the header but also directly by clicking the first two highlighted words at the 'Home' sub-page.

The vision paragraph discusses briefly about the long-term vision that is further clarified by the accompanying image. These provide information to various stakeholder groups varying from the big picture to the general public, to more detailed information to professionals either utilizing blood tests in their work or developing in-vitro diagnostic devices.

The Affinity Mediated Transport (AMT) amplification method, that is the core of the project, is described in its own paragraph. Text briefly discusses the main aspects of the novel method. A link at the end of the paragraph opens a window that shows a diagram of the AMT amplification stages (Figure 5). The diagram provides more details about the AMT amplification method and its implementation.

The project aims are further discussed in the last paragraph. In addition to technical aims, the text also discusses the relevance to cancer management as well as briefly describes the clinical aims, chosen analytes, and their relevance. The figure provides information to all the audiences about the possibilities to use the analysis in the various stages of cancer management.

The 'About' section in the right-hand side provides detailed information about the project in a compact manner.

Home Project Partners Events Contact

Project

The Vision of VerSiLiB is to enable robust usage of proteogenomics readout in in-vitro diagnostics to address unmet medical needs. The multiplexed detection with a single-molecule sensitivity will offer the benefits of DNA and protein biomarker analysis combined into one easy-to-use test. This universal analysis can be applied in the diagnosis of several significant diseases including viral outbreaks, cancers, neuro-degenerative immune and cardiovascular diseases.



Vision: (i) analysis of rare biomarkers in liquid biopsy, (ii) simultaneous analysis of DNA/RNA and protein content (iii) using the novel enzyme-free Affinity Mediated Transport (AMT) amplification method in (iv) low-cost opto-fluidic chips with nL-fL compartments for digital (v) readout at single-molecule sensitivity.

Core idea is a novel enzyme-free Affinity Mediated Transport (AMT) amplification method (Patent No. FI20186055) that unifies the analysis of trace amounts of protein and DNA/RNA analytes. AMT is multipurpose being applicable for various analytes. The key features of AMT include robustness, specificity, speed and accuracy, with respect to currently available enzyme-based detection technologies. See the image.

The project aim is to build a proof-of-concept prototype with a novel read-out unit and opto-fluidic biosensor chip with nanophotonic signal enhancement. The benefits of the technology will be validated in the clinical melanoma management using liquid biopsy samples. In oncology, liquid biopsy holds a promise to become a predictive tool that will personalize follow-up and clinical decisions. We will demonstrate the relevance of the technology by detecting an actionable DNA mutation (BRAF p.V600E) and a highly melanoma-restricted protein (ChondroitinSulphate Proteoglycan 4; CSPG4). BRAF mutation is a predictive biomarker related to the therapy response and CSPG4 blood levels progressively increase with advancing disease stages.



About

- **Project number:** 101046217
- **Project name:** Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy
- **Project acronym:** VerSiLiB
- **Funded by**: European Innovation Council, European Union
- **Call:** HORIZON-EIC-2021-PATHFINDEROPEN-01
- **Duration:** 04/2022-03/2026
- **EU funding:** M€ 2.99

European Innovation Council Funded by the European Union

Funded by the European Union's European Innovation Council under grant agreement No 101046217. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.

Figure 4 'Project' sub-page



Figure 5 Pop-up image in the 'Project' sub-page shows details of the Affinity Mediated Transport amplification method

3.3. 'Partners' sub-page

This sub-page (Figure 6) provides information of the consortium partners. The logo and short introduction of each partner is provided.



Figure 6 'Partner' sub-page

3.4. ‘Events’ sub-page

This sub-page page (Figure 7) lists the events in which the project is disseminated. It contains both past and forthcoming events.



Figure 7 ‘Events’ sub-page

3.5. ‘Contacts’ sub-page

For the contacts, information of the project Coordinator with her email address is given (Figure 8).



Figure 8 'Contact' sub-page

4. Accessibility and Visitor Analytics

Figures on the website contain alternative text descriptions for screen readers improving the accessibility for the visually impaired persons.

The website uses cookies to analyse and report the number of visits. However, the visitors can either accept or reject the cookies being in line with the requirements of the GDPR regulation.

5. Conclusions

The project logo was designed, and it is incorporated in the project website and project materials. It provides a visual identifier to be used widely throughout the project.

The project website was set up, and the content was prepared by the Consortium. The website provides information for both the general public and professionals. The website was published on April 18, 2022. The aim is to refine and add content to the site such as project results, a list of publications and links to the project open science repository and social media once these are defined by the Data Management and Dissemination plans prepared by September 2022.

6. Progress compared to the Description of Action

The project logo was designed, and the website developed and published thus the work is accomplished 100%.